Envoy Medical Reports Full Year 2025 Financial Results

Core Insights - Envoy Medical has received FDA approval to expand its pivotal clinical trial for the fully implanted Acclaim® Cochlear Implant to its final stage, marking a significant milestone for the company [1][2] - The company has strengthened its balance sheet by extinguishing $32 million in debt, which positions it for future growth [3][4] - A transformational capital raise was completed in February 2026, involving established institutional healthcare investors, which will support ongoing clinical trials and future product development [4][5] Financial Performance - For the year ended December 31, 2025, net revenue increased to $241,000 from $225,000 in 2024, primarily driven by sales of the Esteem® FI-AMEI implant and related components [5][21] - Cost of goods sold rose to $874,000, up from $742,000 in 2024, largely due to increased scrap and non-recurring expenses [6][21] - Research and development expenses surged by $2,307,000 to $12,486,000, reflecting additional costs associated with the Acclaim pivotal clinical trial [7][21] - Sales and marketing expenses decreased to $1,220,000 from $1,734,000, attributed to reduced legal fees related to reimbursement work for the Esteem product [8][21] - General and administrative expenses increased by $1,105,000 to $7,931,000, mainly due to severance costs and higher consulting expenses [9][21] Balance Sheet Overview - As of December 31, 2025, total assets were approximately $8.56 million, down from $11.54 million in 2024 [19][20] - Current liabilities increased to $11.56 million from $7.54 million, reflecting higher accounts payable and accrued expenses [20] - The company's stockholders' deficit improved to $(12.16 million) from $(18.84 million) in 2024, indicating a stronger financial position [20] Future Outlook - The company aims to revolutionize hearing health with fully implanted solutions, addressing the needs of millions with severe to profound sensorineural hearing loss [4][5][12] - The Acclaim cochlear implant, which received Breakthrough Device Designation from the FDA in 2019, is expected to be a key product in the company's portfolio [10][13]